Advertisement

Topics

FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma

20:11 EST 13 Nov 2017 | Drugs.com

November 14, 2017 -- AstraZeneca (NYSE:AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of...

Original Article: FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma

NEXT ARTICLE

More From BioPortfolio on "FDA Approves Fasenra (benralizumab) for Severe Eosinophilic Asthma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...